SCHEMBL22743563

SCHEMBL22743563

Cc1n[nH]c(=O)c2c(C)csc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 2/20 0.42
ERCC5 P28715 1/20 0.37
FEN1 P39748 1/20 0.37
DYRK1A Q13627 2/20 0.33
GRIN2D O15399 1/20 0.33
GRIN3B O60391 1/20 0.33
GRIN1 Q05586 1/20 0.33
GRIN2A Q12879 1/20 0.33
GRIN2B Q13224 1/20 0.33
GRIN2C Q14957 1/20 0.33
GRIN3A Q8TCU5 1/20 0.33
JAK1 P23458 1/20 0.33
TNKS O95271 1/20 0.31
PARP1 P09874 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31
ADORA1 P30542 1/20 0.31
PDE1A P54750 1/20 0.31
PDE1B Q01064 1/20 0.31
PDE3B Q13370 1/20 0.31
PDE1C Q14123 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12617155 0.72 ADORA2A (0.35) PDPK1DYRK1A
SCHEMBL13764548 0.69 PDPK1 (0.44) PDPK1ERCC5FEN1GRIN2DGRIN3B
SCHEMBL24000490 0.68 GRIN2D (0.43) PDPK1DYRK1AGRIN2DGRIN3BGRIN1
SCHEMBL14826495 0.67 ADORA2A (0.42) PDPK1DYRK1AGRIN2DGRIN3BGRIN1
SCHEMBL20229834 0.67 ADORA2A (0.55) PDPK1PARP1ADORA1
SCHEMBL25170501 0.67 PDPK1 (0.54) PDPK1ERCC5FEN1TNKSPARP1
SCHEMBL25331496 0.67 ADORA2A (0.47) PDPK1DYRK1ATNKSPARP1TNKS2
SCHEMBL1463831 0.66 PDPK1 (0.41) PDPK1ERCC5FEN1
SCHEMBL18639718 0.64 PDPK1 (0.40) PDPK1ERCC5FEN1GRIN2DGRIN3B
SCHEMBL25332682 0.64 PDPK1 (0.34) PDPK1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020239076-A1 PYRIDAZINONE DERIVATIVES AS THYROXINE RECEPTOR-Β AGONISTS AND APPLICATION THEREOF 南京明德新药研发有限公司 2020-12-03 WO disclosed